FBLG trades 23270.6% below Wall Street's consensus target of $180.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FBLG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, FibroBiologics, Inc. Common Stock (FBLG) has a Wall Street consensus price target of $180.00, based on estimates from 3 covering analysts. With the stock currently trading at $0.81, this represents a potential upside of +23270.6%. The company has a market capitalization of $2M.
Analyst price targets range from a low of $180.00 to a high of $180.00, representing a 0% spread in expectations. The median target of $180.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FBLG trades at a trailing P/E of -0.1x. Analysts expect EPS to grow +49.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MESOMesoblast Limited | $2.0B | $15.50 | $11.50 | -20.0% | Buy | — | 11 |
NKTRNektar Therapeutics | $1.3B | $65.70 | $149.60 | +145.3% | Buy | — | 33 |
MDXGMiMedx Group, Inc. | $545M | $3.67 | $10.00 | +172.5% | Buy | — | 15 |
RGENRepligen Corporation | $7.1B | $126.57 | $158.67 | +20.2% | Buy | 65.9x | 24 |
FATEFate Therapeutics, Inc. | $251M | $2.15 | $5.50 | +163.2% | Buy | — | 31 |
CELCCelcuity Inc. | $4.4B | $89.93 | $153.22 | +74.6% | Buy | — | 12 |
VCELVericel Corporation | $2.1B | $40.47 | $52.67 | +31.3% | Buy | 84.9x | 14 |
RCUSArcus Biosciences, Inc. | $2.7B | $27.23 | $31.00 | +27.5% | Buy | — | 18 |
ILMNIllumina, Inc. | $24.5B | $161.38 | $151.40 | -6.5% | Buy | 31.0x | 50 |
TMOThermo Fisher Scientific Inc. | $172.4B | $464.01 | $599.70 | +29.1% | Buy | 18.7x | 42 |
Quick answers to the most common questions about buying FBLG stock.
The consensus Wall Street price target for FBLG is $180, representing 23270.6% upside from the current price of $0.8055. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FBLG has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $180 implies 23270.6% upside from current levels.
FBLG's current price is $0.8055 with a consensus target of $180 (23270.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $180 for FBLG, while the most conservative target is $180. The consensus of $180 represents the median expectation. These targets typically reflect 12-month expectations.
FBLG is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FBLG stock forecast based on 3 Wall Street analysts shows a consensus price target of $180, with estimates ranging from $180 (bear case) to $180 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on FBLG, with a "Buy" consensus rating and $180 price target (23270.6% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FBLG analyst price targets range from $180 to $180, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $180 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.